Search Results

Ziopharm Oncology, Inc. today highlighted recent operational and corporate updates.

Ziopharm Oncology, Inc., announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, was the inaugural presenter at Aldevron’s Virtual Breakthrough Speaker Series.

Ziopharm Oncology, Inc., provided corporate updates for the second quarter of 2021, ended June 30, 2021.

Ziopharm Oncology, Inc., announced financial results for the third quarter ended September 30, 2021 and provided a business update.

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the appointment of Kevin S. Boyle, Sr. as its new Chief Executive Officer, effective today.

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences:

Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm.

Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has informed the Company of his intention to step down from the role effective December 31, 2020 to pursue another opportunity. The Company has initiated a search for a new Chief Financial Officer. Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, said, “On behalf of everyone at Ziopharm,